S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2014 Results on Thursday, January 29, 2015 (2015/1/21)|
|Alexion to Present at the J.P. Morgan 33rd Annual Healthcare Conference (2015/1/5)|
|Alexion tumbles on failed transplant drug trial (2015/1/7)|
|Alexion Reports Fourth Quarter and Full Year 2014 Results and Provides Financial Guidance for 2015 (2015/1/29)|
|Soliris® (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Myasthenia Gravis (2014/12/10)|
|Alexion Appoints David L. Hallal as Chief Executive Officer, Effective April 1, 2015 (2015/1/29)|
|NICE Issues Final Positive Recommendation for National Commissioning of Soliris® (eculizumab) for All Patients with aHUS in England (2014/11/27)|
|Alexion Provides Update on Phase 2 Clinical Trial with Eculizumab in Antibody Mediated Rejection (AMR) in Living-Donor Kidney Transplant Recipients (2015/1/7)|
|Alexion Completes Rolling BLA Submission to U.S. FDA for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia (2014/12/30)|
|Alexion Announces $500 Million Share Repurchase Program (2014/12/15)|
Click above to view more mutual fund data and stats for alxn - Alexion Pharmaceuticals Inc.